Expanded Access Submission Receipts Report 2012

First Page		Document Content
Treatment IND Medicine Information Communications protocol Investigational New Drug Pharmacology Health Expanded access		Expanded Access Submission Receipts Report 2012 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 45,24 KB Share Document on Facebook

	Morphochem’s Investigational New Drug (IND) application accepted by FDA – Novel antibacterial for IV treatment of CDI ready to move to Phase 2 Munich (Germany), June 22, 2016 — Morphochem, a clinical-stage pharmace DocID: 1uvYN - View Document
	Microsoft Worddoc DocID: 1qVAJ - View Document
	Special circumstances regarding expanded access at Stanford In most circumstances, medical research using investigational drugs, biologics and devices DocID: 1qU9m - View Document
	Expanded Access to Investigational Drugs and Biologics _______________________________When All Else Fails__________________________ DocID: 1pfnU - View Document
	Emory IRB Guidance for Investigators Guidance for the IRB Submission of an Expanded Access IND (Treatment or Emergency use) of an Unapproved Drug The guidance below is for use of an unapproved drug to treat a patient or DocID: 19Vgb - View Document